Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
Year: 2011
Type: article
Authors: Paul B. Chapman, Axel Hauschild, Caroline Robert, James Larkin, J.B.A.G. Haanen, A. Ribas, David Hogg, Steven O’Day, Paolo A. Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, J. A. Sosman, Claus Garbe, R. J. Lee, K. B. Nolop, B. Nelson, Jeannie Hou, Keith T. Flaherty, Grant A. McArthur
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3200879216